Q3 2018 EPS Estimates for Hologic, Inc. (HOLX) Increased by Analyst
Hologic, Inc. (NASDAQ:HOLX) – Stock analysts at Jefferies Group lifted their Q3 2018 earnings per share estimates for Hologic in a research note issued to investors on Thursday. Jefferies Group analyst R. Denhoy now expects that the medical equipment provider will earn $0.57 per share for the quarter, up from their prior forecast of $0.54. Jefferies Group also issued estimates for Hologic’s Q4 2018 earnings at $0.60 EPS, FY2018 earnings at $2.25 EPS, FY2019 earnings at $2.52 EPS and FY2020 earnings at $2.83 EPS.
Several other analysts also recently issued reports on the company. Goldman Sachs Group upgraded Hologic from a “buy” rating to a “conviction-buy” rating and increased their price target for the company from $45.00 to $50.00 in a report on Friday, December 8th. Zacks Investment Research downgraded Hologic from a “hold” rating to a “sell” rating in a report on Tuesday, October 17th. Cowen upgraded Hologic from a “market perform” rating to an “outperform” rating and set a $51.00 price target for the company in a report on Monday, December 11th. Needham & Company LLC reiterated a “buy” rating and issued a $50.00 price target on shares of Hologic in a report on Friday, November 3rd. Finally, BidaskClub downgraded Hologic from a “hold” rating to a “sell” rating in a report on Saturday, January 13th. One research analyst has rated the stock with a sell rating, five have issued a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $48.36.
Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Thursday, February 8th. The medical equipment provider reported $0.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.50 by $0.05. Hologic had a return on equity of 20.75% and a net margin of 34.53%. The firm had revenue of $791.10 million during the quarter, compared to the consensus estimate of $785.80 million. During the same period in the prior year, the firm earned $0.52 EPS. The firm’s quarterly revenue was up 7.7% compared to the same quarter last year.
In other Hologic news, VP Karleen Marie Oberton sold 1,023 shares of the company’s stock in a transaction dated Monday, November 20th. The shares were sold at an average price of $39.84, for a total value of $40,756.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.79% of the company’s stock.
Hedge funds have recently modified their holdings of the company. Grove Bank & Trust lifted its position in shares of Hologic by 115.8% during the third quarter. Grove Bank & Trust now owns 2,860 shares of the medical equipment provider’s stock worth $105,000 after purchasing an additional 1,535 shares during the last quarter. Hall Laurie J Trustee lifted its position in shares of Hologic by 10.2% during the second quarter. Hall Laurie J Trustee now owns 2,425 shares of the medical equipment provider’s stock worth $110,000 after purchasing an additional 225 shares during the last quarter. MPS Loria Financial Planners LLC bought a new position in shares of Hologic during the second quarter worth about $191,000. NuWave Investment Management LLC bought a new position in shares of Hologic during the fourth quarter worth about $199,000. Finally, National Asset Management Inc. bought a new position in shares of Hologic during the second quarter worth about $203,000. 92.77% of the stock is currently owned by institutional investors and hedge funds.
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.